세계의 더말 필러 시장 : 인사이트, 경쟁 구도, 시장 예측(2032년)

Dermal Fillers Market by Product Type (Biodegradable Fillers and Non-Biodegradable Fillers), Material (Hyaluronic Acid (HA), Calcium hydroxylapatite (CaHA), Poly-L-lactic acid (PLLA), Polymethylmethacrylate (PMMA), and Others), Gender (Male and Female), End-User (Hospitals, Dermatology Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising number of cosmetic procedures performed globally and increasing product development and launches activities by key players.

The dermal fillers market was valued at USD 6,238.22 million in 2024, growing at a CAGR of 8.25% during the forecast period from 2025 to 2032 to reach USD 11,695.43 million by 2032. The demand for dermal fillers is driven by several key factors. Firstly, the rising number of cosmetic procedures performed globally is primarily attributed to the aging population and a growing desire to maintain a youthful appearance, alongside increasing aesthetic consciousness. Secondly, there is a strong shift towards minimally invasive cosmetic procedures due to their convenience, shorter recovery times, and lower costs compared to traditional surgeries. Lastly, increasing investments and continuous innovations in the research and development of dermal fillers are further propelling market growth. These factors collectively are expected to drive significant expansion in the dermal fillers market during the forecast period from 2025 to 2032.

Dermal Fillers Market Dynamics:

According to data from the International Society of Aesthetic Plastic Surgery (ISAPS, 2024), in 2023, more than 35 million aesthetic procedures, both surgical and non-surgical, were performed globally. Notably, face and head procedures experienced substantial growth, accounting for over 6.5 million procedures, marking a 19.6% increase from the previous year. In 2022, this upward trend included more than 14.9 million surgical and 18.8 million non-surgical procedures, underscoring the growing global demand for aesthetic enhancements.

Dermal fillers play a critical role in this landscape. They are often used alongside surgical procedures, either as a preliminary enhancement or a post-surgical refinement tool. For instance, fillers are commonly applied to smooth scars, restore facial volume, or enhance features following facelifts or rhinoplasty. This integration further solidifies the relevance of dermal fillers as a complementary and standalone solution in the field of aesthetic medicine.

The rising number of cosmetic procedures worldwide is a key driver of growth in the dermal fillers market. This surge is fueled by increasing aesthetic awareness, a shift toward minimally invasive treatments, and improved accessibility to advanced cosmetic procedures across the globe. ISAPS also highlighted regional trends that reinforce this global momentum. In 2023:

• Brazil performed over 3 million aesthetic procedures, maintaining its position as one of the major countries in aesthetic procedures.
• India reported 1,028,723 aesthetic procedures, of which 496,931 were non-surgical, a substantial portion involving dermal fillers, as one of the leading countries in cosmetic procedures.
• The National Institutes of Health (2024) further reported that India ranked second globally country in the number of non-surgical facial rejuvenation procedures performed by plastic surgeons, with over 1 million aesthetic procedures conducted annually. In 2022 alone, the country recorded approximately 370,656 cosmetic surgeries, showcasing sustained demand across surgical and non-surgical procedures.
• In the United Kingdom, data from the British Association of Aesthetic Plastic Surgeons (2023) showed that, in 2022, over 31,057 cosmetic procedures were conducted, further contributing to the global expansion of the market.

In response to rising demand, key industry players are intensifying R&D efforts to develop next-generation dermal fillers that offer improved efficacy, safety, and longevity. A notable example is Evolus, which in April 2025 announced the commercial launch of Evolysse(TM) Form and Evolysse(TM) Smooth, an injectable hyaluronic acid (HA) gels designed to smooth wrinkles and restore volume, particularly in areas such as the nasolabial folds (lines running from the nose to the corners of the mouth).

However, the complications and safety concerns associated with dermal fillers and high treatment cost, among others are some of the key constraints that may limit the growth of the dermal fillers market.

Dermal Fillers Market Segment Analysis:

Dermal Fillers Market by Product Type (Biodegradable Fillers and Non-Biodegradable Fillers), Material (Hyaluronic Acid (HA), Calcium hydroxylapatite (CaHA), Poly-L-lactic acid (PLLA), Polymethylmethacrylate (PMMA), and Others), Gender (Male and Female), End-User (Hospitals, Dermatology Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the material segment of the dermal fillers market, the hyaluronic acid (HA) category is estimated to account for the largest market share in 2024. The growth of the hyaluronic acid (HA) segment within the dermal fillers market is being propelled by several key factors, including the increasing adoption of HA-based fillers, the rising number of aesthetic procedures worldwide, and the wide range of benefits and applications associated with this category.

According to the International Society of Aesthetic Plastic Surgery (ISAPS, 2023), over 5,564,866 non-surgical cosmetic procedures involving hyaluronic acid-based dermal fillers were performed globally in 2023, up from 4,312,037 procedures in 2022. This steady upward trend is largely driven by growing disposable incomes, heightened awareness of cosmetic treatments, and an increasing focus on personal appearance, particularly among urban and millennial populations.

One of the primary advantages of HA-based fillers is that hyaluronic acid is a naturally occurring substance in the body, which significantly reduces the risk of allergic reactions. These fillers are well-known for their ability to restore facial volume, hydrate the skin, smooth wrinkles, and enhance facial contours. HA fillers integrate seamlessly with the skin, delivering a natural look and feel that appeals to patients seeking subtle yet effective rejuvenation.

Another important benefit of HA fillers is their capacity to provide immediate visible results. Upon injection, these fillers quickly replenish volume and reduce wrinkles, offering noticeable cosmetic improvements without extended downtime. This instant gratification is especially attractive to patients who desire quick, non-invasive enhancements for social or professional occasions. Furthermore, the reversibility of HA fillers is a standout feature that enhances patient confidence and physician control. In cases of dissatisfaction or adverse reactions, the filler can be safely dissolved using an enzyme called hyaluronidase, providing an added layer of safety and flexibility in treatment.

The segment's growth is also supported by continuous product innovations and regulatory approvals from leading industry players. For example, in May 2023, Allergan Aesthetics, an AbbVie company, announced the U.S. FDA approval of SKINVIVE(TM) by JUVEDERM(R), a novel hyaluronic acid intradermal microdroplet injection designed to improve skin smoothness in adults over 21. SKINVIVE(TM) is the first and only HA-based treatment of its kind available in the U.S., offering results that can last up to six months with optimal treatment.

Thus, the factors mentioned above are likely to boost the market segment and thereby increase the overall market of dermal fillers across the globe.

North America is expected to dominate the overall dermal fillers market:

North America is projected to hold the largest share of the dermal fillers market in 2024, driven by several key factors. This regional dominance can be primarily attributed to the rising number of cosmetic procedures performed, fueled by an aging population and an increasing desire to maintain a youthful appearance. Additionally, the growing demand for minimally invasive cosmetic treatments, coupled with a well-established healthcare infrastructure, has significantly contributed to market growth. Increased awareness and widespread acceptance of aesthetic procedures further support this trend. Moreover, numerous product approvals and new launches by leading market players are strengthening North America's position. Collectively, these factors are expected to sustain North America's leadership in the dermal fillers market throughout the forecast period from 2025 to 2032.

According to data from the International Society of Aesthetic Plastic Surgery (ISAPS, 2023), the United States led the world in the number of aesthetic procedures performed, with 6,196,701 total procedures, including 4,405,599 non-surgical cosmetic treatments. Among these non-surgical procedures, 84,817 involved Calcium Hydroxylapatite-based fillers, while 712,225 utilized hyaluronic acid (HA) dermal fillers. Additionally, the American Society of Plastic Surgeons (2023) reported that over 9.5 million plastic surgeries were performed in the U.S. in 2023.

The rising volume of aesthetic procedures is a significant driver of the dermal fillers market growth in the region. This increase reflects growing demand for non-surgical, minimally invasive treatments that offer quick results and minimal downtime. The surge is fueled by heightened awareness, broader acceptance of cosmetic enhancements, and an expanding aging population seeking effective solutions for maintaining a youthful appearance.

Furthermore, key market players are intensifying their research and development efforts to introduce and commercialize advanced dermal filler products tailored to meet regional needs. For example, in June 2023, Galderma announced the U.S. Food and Drug Administration (FDA) approval of Restylane(R) Eyelight, designed specifically for the treatment of under-eye hollows (dark shadows) in adults over 21. This product is the first and only HA dermal filler in the U.S. formulated with NASHA(R) Technology to address volume loss under the eyes, delivering natural-looking results.

Similarly, in February 2022, Allergan Aesthetics, an AbbVie company, announced FDA approval for JUVEDERM(R) VOLBELLA(R) XC to treat infraorbital hollows in adults over 21. This versatile filler is also used for lip augmentation and correction of perioral lines, enhancing overall facial aesthetics by improving the appearance of under-eye hollows.

Collectively, the increasing volume of cosmetic procedures combined with strategic product launches is propelling the demand for dermal fillers in North America, solidifying its position as a leading region in the global dermal fillers market.

Dermal Fillers Market Key Players:

Some of the key market players operating in the dermal fillers market include AbbVie Inc., Galderma, Merz Pharma, Tiger BioSciences, Teoxane SA, Crown Laboratories, Inc., Prollenium Medical Technologies, Inc., Johnson & Johnson Services, Inc., Anika Therapeutics, Inc., Fillmed, VIVACY Laboratories, Sinclair, Medytox, HUGEL, Inc., Ipsen Pharma, Evolus, Inc., Symatese, LG Chem, KORU Pharma Co., LTD., BIOPLUS CO., LTD., and others.

Recent Developmental Activities in the Dermal Fillers Market:

• In February 2025, Crown Laboratories, Inc., a privately held global leader in skincare innovation, announced the successful acquisition of Revance Therapeutics, Inc., a pioneering biotechnology company specializing in dermal fillers. Through this acquisition, Crown significantly enhanced its product portfolio and expanded its global presence in the dermal fillers market, particularly with RHA Redensity(TM) and its range of RHA(R) 2, RHA(R) 3, and RHA(R) 4 based dermal fillers.
• In October 2024, Allergan Aesthetics, an AbbVie company, announced the national availability of JUVEDERM(R) VOLUMA(R) XC for the treatment of temple hollowing. This hyaluronic acid (HA) filler is approved for addressing moderate to severe temple hollowing in adults over 21. As the leading HA dermal filler brand preferred by both patients and providers, the JUVEDERM(R) Collection of Fillers now offers the broadest range of treatment indications to help patients achieve their aesthetic goals.
• In October 2022, Prollenium Medical Technologies Inc. completed the acquisition of SoftFil(R), a pioneering French brand known for its advanced micro-cannulas and innovative cosmetic products. Through this strategic acquisition, Prollenium strengthened its position in the global dermal fillers market by expanding its portfolio with Revanesse(R), a brand of hyaluronic acid-based dermal fillers, further enhancing its capabilities in delivering cutting-edge aesthetic solutions.

Key takeaways from the dermal fillers market report study

• Market size analysis for current dermal fillers market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the dermal fillers market.
• Various opportunities available for the other competitors in the dermal fillers market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current dermal fillers market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for dermal fillers market growth in the coming future?

Target audience who can benefit from this dermal fillers market report study

• Dermal filler product providers
• Research organizations and consulting companies
• Dermal fillers-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in dermal fillers
• Various end-users who want to know more about the dermal fillers market and the latest technological developments in the dermal fillers market.

Frequently Asked Questions for the Dermal Fillers Market:

1. What are dermal fillers?

• Dermal fillers are injectable substances used in aesthetic medicine to restore volume, smooth out wrinkles and fine lines, and enhance facial contours. They are a popular non-surgical cosmetic treatment designed to rejuvenate the face and other areas by filling in areas that have lost volume or elasticity due to aging, genetics, or environmental factors.

2. What is the market for dermal fillers?

• The dermal fillers market was valued at USD 6,238.22 million in 2024, growing at a CAGR of 8.25% during the forecast period from 2025 to 2032 to reach USD 11,695.43 million by 2032.

3. What are the drivers for the dermal fillers market?

• The demand for dermal fillers is being fuelled by key drivers. The growing number of cosmetic procedures worldwide is closely linked to an aging population and a heightened desire among individuals to preserve a youthful appearance, supported by rising aesthetic awareness. Further, there is an increasing preference for minimally invasive treatments that offer the benefits of convenience, reduced recovery time, and cost-effectiveness compared to traditional surgical options. In addition, sustained investment and ongoing innovation in dermal filler research and development are contributing to the introduction of advanced products with improved safety, efficacy, and longevity. Together, these trends are expected to drive substantial growth in the dermal fillers market over the forecast period from 2025 to 2032.

4. Who are the key players operating in the dermal fillers market?

• Some of the key market players operating in the dermal fillers market include AbbVie Inc., Galderma, Merz Pharma, Tiger BioSciences, Teoxane SA, Crown Laboratories, Inc., Prollenium Medical Technologies, Inc., Johnson & Johnson Services, Inc., Anika Therapeutics, Inc., Fillmed, VIVACY Laboratories, Sinclair, Medytox, HUGEL, Inc., Ipsen Pharma, Evolus, Inc., Symatese, LG Chem, KORU Pharma Co., LTD., BIOPLUS CO., LTD., and others.

5. Which region has the highest share in the dermal fillers market?

• North America is projected to hold the largest share of the dermal fillers market in 2024, driven by several key factors. This regional dominance is primarily attributed to the rising number of cosmetic procedures performed, fueled by an aging population and an increasing desire to maintain a youthful appearance. Additionally, the growing demand for minimally invasive cosmetic treatments, coupled with a well-established healthcare infrastructure, has significantly contributed to market growth. Increased awareness and widespread acceptance of aesthetic procedures further support this trend. Moreover, numerous product approvals and new launches by leading market players are strengthening North America's position. Collectively, these factors are expected to sustain North America's leadership in the dermal fillers market throughout the forecast period from 2025 to 2032.

Table of Contents

1. Dermal Fillers Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Dermal Fillers Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Dermal Fillers Market Key Factors Analysis

• 5.1. Dermal Fillers Market Drivers
  • 5.1.1. The rising number of cosmetic procedures performed globally
  • 5.1.2. The increasing demand for minimally invasive cosmetic procedures
  • 5.1.3. Increasing investments and innovations in the research and development of dermal fillers
• 5.2. Dermal Fillers Market Restraints and Challenges
  • 5.2.1. Complications and safety concerns associated with dermal fillers
  • 5.2.2. High treatment cost
• 5.3. Dermal Fillers Market Opportunity
  • 5.3.1. Development of more advanced biodegradable and bioresorbable fillers

6. Dermal Fillers Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Dermal Fillers Market Assessment

• 7.1. By Product Type
  • 7.1.1. Biodegradable Fillers
  • 7.1.2. Non-Biodegradable Fillers
• 7.2. By Material
  • 7.2.1. Hyaluronic Acid (HA)
  • 7.2.2. Calcium hydroxylapatite (CaHA)
  • 7.2.3. Poly-L-lactic acid (PLLA)
  • 7.2.4. Polymethylmethacrylate (PMMA)
  • 7.2.5. Others
• 7.3. By Gender
  • 7.3.1. Male
  • 7.3.2. Female
• 7.4. By End-User
  • 7.4.1. Hospitals
  • 7.4.2. Dermatology Clinics
  • 7.4.3. Others
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. United States Dermal Fillers Market Size in USD million (2022-2032)
    • 7.5.1.2. Canada Dermal Fillers Market Size in USD million (2022-2032)
    • 7.5.1.3. Mexico Dermal Fillers Market Size in USD million (2022-2032)
  • 7.5.2. Europe
    • 7.5.2.1. France Dermal Fillers Market Size in USD million (2022-2032)
    • 7.5.2.2. Germany Dermal Fillers Market Size in USD million (2022-2032)
    • 7.5.2.3. United Kingdom Dermal Fillers Market Size in USD million (2022-2032)
    • 7.5.2.4. Italy Dermal Fillers Market Size in USD million (2022-2032)
    • 7.5.2.5. Spain Dermal Fillers Market Size in USD million (2022-2032)
    • 7.5.2.6. Rest of Europe Dermal Fillers Market Size in USD million (2022-2032)
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. China Dermal Fillers Market Size in USD million (2022-2032)
    • 7.5.3.2. Japan Dermal Fillers Market Size in USD million (2022-2032)
    • 7.5.3.3. India Dermal Fillers Market Size in USD million (2022-2032)
    • 7.5.3.4. Australia Dermal Fillers Market Size in USD million (2022-2032)
    • 7.5.3.5. South Korea Dermal Fillers Market Size in USD million (2022-2032)
    • 7.5.3.6. Rest of Asia-Pacific Dermal Fillers Market Size in USD million (2022-2032)
  • 7.5.4. Rest of the World (RoW)
    • 7.5.4.1. Middle East Dermal Fillers Market Size in USD million (2022-2032)
    • 7.5.4.2. Africa Dermal Fillers Market Size in USD million (2022-2032)
    • 7.5.4.3. South America Dermal Fillers Market Size In USD Million (2022-2032)

8. Dermal Fillers Market Company and Product Profiles

• 8.1. AbbVie Inc.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Galderma
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Merz Pharma
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Tiger BioSciences
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Teoxane SA
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Crown Laboratories, Inc.
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Prollenium Medical Technologies, Inc.
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Johnson & Johnson Services, Inc.
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Anika Therapeutics, Inc.
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Fillmed
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. VIVACY Laboratories
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Sinclair
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Medytox
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. HUGEL, Inc.
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Ipsen Pharma
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Evolus, Inc.
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Symatese
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. LG Chem
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. KORU Pharma Co., LTD.
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. BIOPLUS CO., LTD.
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us